Methods: Treatment-experienced Doxorubicin clinical trial GT2/3 HCV-infected patients, the majority of whom had cirrhosis, were enrolled in a single arm, open-label study and received SOF 400 mg daily + PegIFN 180 μg weekly + RBV 1000–1200 mg daily for 12 weeks. The primary endpoint was SVR12. Secondary objectives included safety and tolerability, resistance, and additional efficacy outcomes. Results: 47 patients were enrolled and treated; 51% had HCV GT3, 55% had compensated cirrhosis, median age 57 (range 39–72), median BMI 31 (range 21–53), 36% were IL28BCC. Overall, 42/47 (89%) achieved SVR12 with 2 virologic failures (relapses, both GT3), 2 patients have no post-treatment

follow up, and one had an early treatment discontinuation without achieving HCV RNA < LLOQ. Efficacy results are tabulated. Adverse events (AE) was consistent with PR. The most common AEs were: flu-like symptoms (55%), fatigue (32%), anemia (30%), neutropenia (23%), and nausea (17%). SAEs occurred in 4 (9%) patients; no individual SAE occurring in >1 patient. One subject discontinued treatment due to an adverse event of body pain and was then lost to follow up. Conclusions: SOF + PR for 12 weeks demonstrated high efficacy in treatment-experienced Opaganib GT2/3 patients who have historically low response rates and limited treatment options.

SOF + PR was generally safe and well tolerated with low discontinuation rates and adverse events consistent with PegIFN + RBV treatment. SVR12 Rates in the LONESTAR-2 Study Population SVR12 Overall 42/47 (89%) Genotype 2

Overall 22/23 (96%) Genotype 2 Non-cirrhotic 9/9 (100%) Genotype 2 cirrhotic 13/14 (93%) Genotype 3 Overall 20/24 (83%) Genotype 3 Non-cirrhotic 10/12 (83%) Genotype 3 cirrhotic 10/12 (83%) SY LAU,1 RJ WOODMAN,2 MCE公司 R MCCORMICK,1 R WUNDKE,1 AJ WIGG1 1Hepatology and Liver Transplant Medicine Unit, Flinders Medical Centre, Adelaide, Australia, 2Division of General Practice, School of Medicine, Flinders University, Adelaide, Australia Introduction: Chronic liver disease affects 6 million Australians, and has significant economic impacts on the health care system. A chronic disease management (CDM) model for chronic liver failure (CLF) has been developed by our group and demonstrated an improvement in outpatient clinic attendance and quality of care in a randomized controlled trial setting1. However, the study did not demonstrate a reduction in hospital utilization during the 12-month study period. Our primary aim of this study was to re-examine hospital utilization by this study cohort in the longer term, after enrolment into the CDM program. Methods: For patients enrolled in the prior study data on hospitalization was reviewed for up to 24 months pre and 60 months post entry into a the CDM program. The 20 patients who acted as controls in the original CDM trial were crossed over into the CDM program at 12 months, providing hospitalization data post entry into the CDM program.